<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group|1</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">9662244</article-id><article-id pub-id-type="pmc">2062954</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Helle</surname><given-names>S. I.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Geisler</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Poulsen</surname><given-names>J. P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hestdal</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Meadows</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Collins</surname><given-names>W.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tveit</surname><given-names>K. M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Holly</surname><given-names>J. M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>L&#x000f8;nning</surname><given-names>P. E.</given-names></name></contrib></contrib-group><aff>Department of Oncology, Haukeland University Hospital, Bergen, Norway.</aff><pub-date pub-type="ppub"><month>7</month><year>1998</year></pub-date><volume>78</volume><issue>1</issue><fpage>14</fpage><lpage>20</lpage><abstract><p>Fourteen patients suffering from advanced colorectal (n = 7), pancreatic (n = 4) or gastric (n = 3) carcinomas received treatment with microencapsulated octreotide pamoate 90 mg i.m. every 4 weeks (n = 4), 160 mg i.m. every 4 weeks (n = 4) or 160 mg i.m. every 2 weeks (n = 6). Two patients had stable disease, one for 4 and one for 6 months. Plasma insulin-like growth factor (IGF)-I decreased by 49-53%, IGF-II by 27-37% and total IGF-binding protein (IGFBP)-3 by 16-19%, whereas IGFBP-1 increased by 35-55%. Insulin and C-peptide levels decreased by 29-38% and 41-46% respectively. A non-significant decrease in urinary GH secretion and an increase in the ratio of fragmented to intact IGFBP-3 as well as IGFBP-3 protease activity was seen. The increase in IGFBP-3 fragmentation correlated negatively with alterations in IGF-I and IGF-II (P &#x0003c; 0.05). We conclude that microencapsulated octreotide administered in doses up to 160 mg every 2 weeks is well tolerated and has pronounced effects on several components of the IGF system in plasma. In addition, changes in IGFBP-3 protease activity because of cancer may contribute to alterations in IGF-I and -II, indicating the importance of measuring this parameter in addition to IGFs and IGFBPs when evaluating alterations in IGF-I.</p><sec sec-type="scanned-figures"><title>Images</title><fig id="F1"><label>Figure 2</label><graphic xlink:href="brjcancer00001-0021-a" xlink:role="17"/></fig></sec></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00001-0018.tif" xlink:title="scanned-page" xlink:role="14" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00001-0019.tif" xlink:title="scanned-page" xlink:role="15" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00001-0020.tif" xlink:title="scanned-page" xlink:role="16" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00001-0021.tif" xlink:title="scanned-page" xlink:role="17" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00001-0022.tif" xlink:title="scanned-page" xlink:role="18" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00001-0023.tif" xlink:title="scanned-page" xlink:role="19" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00001-0024.tif" xlink:title="scanned-page" xlink:role="20" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

